Kết quả điều trị u máu thể nông ở trẻ sơ sinh bằng laser màu xung kết hợp bôi timolol tại Bệnh viện Da liễu Trung ương

Infantile hemangioma (IH) is the most common benign vascular tumor in infancy, often presenting significant clinical challenges for both patients and clinicians. While various treatment modalities exist, including systemic and topical medications, and interventional procedures, optimizing therapeutic outcomes with enhanced safety remains a crucial area of research. Particularly, the combination of pulsed dye laser (PDL) and topical timolol has shown promising results globally for superficial infantile hemangiomas. However, robust evidence specifically within the Vietnamese population is limited. This study addresses this gap by aiming to evaluate the efficacy and safety of pulsed dye laser combined with topical timolol in treating superficial infantile hemangiomas in infants, thereby contributing valuable data to local clinical practice and potentially improving patient care.

Dermatologists, pediatricians, and other healthcare professionals involved in the diagnosis and treatment of infantile hemangioma, as well as medical researchers interested in pediatric dermatology.

This interventional comparative study aimed to assess the efficacy and safety of combined pulsed dye laser (PDL) and topical timolol therapy for superficial infantile hemangiomas, comparing it against topical timolol monotherapy. Conducted on 69 patients at the National Hospital of Dermatology and Venereology, the research divided participants into two groups: Group I received combination treatment (n=36), while Group II received topical timolol alone (n=33). Outcomes, including lesion area reduction and thickness, were evaluated at baseline and at 4, 8, 12, and 16 weeks post-treatment. Results demonstrated superior outcomes for the combination therapy. Group I exhibited a significantly higher reduction in lesion area, reaching 76.04% by 16 weeks compared to 52.03% in Group II (p < 0.01). Furthermore, ultrasound measurements revealed a statistically significant reduction in lesion thickness in Group I, with an average reduction of 1.39 mm by 16 weeks, a finding not observed as significant in Group II. While Group I reported mild blistering in 4 out of 36 patients as a side effect, Group II recorded no side effects. The study concludes that the combined therapy of topical timolol maleate and pulsed dye laser offers an effective and safe treatment option for superficial infantile hemangioma. These findings strongly support the adoption of this combination approach in clinical settings for improved management of this common pediatric vascular tumor.